Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 5, Issue 1, Pages 91-97Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECP.11.68
Keywords
calcineurin inhibitor; pimecrolimus; randomized controlled trials; seborrheic dermatitis; systematic review; treatment
Categories
Ask authors/readers for more resources
Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin disorder that manifests as erythema, scaling and pruritus in sebum gland-rich areas of the skin. The objective of this article is to evaluate the clinical efficacy of pimecrolimus 1% cream in the treatment of seborrheic dermatitis compared with corticosteroids, antimycotics, placebo or no intervention. Pimecrolimus 1% cream appears to be a well-tolerated and effective treatment for seborrheic dermatitis. It has comparable efficacy, in terms of decreasing severity of erythema, scaling and pruritus, to the standard treatments: topical corticosteroids and antimycotics. However, future studies with more standardized measures of treatment outcome are recommended. More studies may also be conducted to further evaluate pimecrolimus 1% cream as a long-term maintenance therapy for seborrheic dermatitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available